Baretinib Tablets can treat moderately to severely active rheumatoid arthritis. The main ingredient of baricitinib tablets is baricitinib, which is indicated for adult patients with moderately to severely active rheumatoid arthritis who are refractory to or intolerant of one or more disease-modifying antirheumatic drugs (DMARDs), and may be used in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs. The most common side effects associated with baricitinib treatment include upper respiratory tract infections, headache, diarrhea, and inflammatory reactions in the nose and upper pharynx. The drug Baretinib tablets is contraindicated in pregnant women. The drug is recommended to be taken under the medical advice of a doctor, and should not be used blindly on its own, as an overdose can affect the patient’s health and can cause adverse reactions.